A Uniform Ultra-Small Microsphere/SAIB Hybrid Depot with Low Burst Release for Long-Term Continuous Drug Release

Pharmaceutical Research

Volumn 32, Issue 11, 2015, Pages 3708-3721

  Lin, Xia ^a,b   Xu, Yuhong ^a   Tang, Xing ^c   Zhang, Yan ^d   Chen, Jian ^a   Zhang, Yu ^c   He, Haibing ^c   Yang, Ziyi ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b JIANGNAN UNIVERSITY   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^d SHENYANG UNIVERSITY   (China)

Author keywords

biocompatibility; burst release; continuous drug release; degradation in vivo; uniform ultra small microsphere SAIB hybrid depot

Indexed keywords

MICROSPHERE; RISPERIDONE; SUCROSE ACETATE ISOBUTYRATE; DELAYED RELEASE FORMULATION; DRUG CARRIER; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CELL INFILTRATION; DEGRADATION; DEGRADATION KINETICS; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; EMULSION; ENCAPSULATION; FIBROBLAST; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PLASMA CELL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SLOW DRUG RELEASE; SOLVENT EXTRACTION; SUSTAINED DRUG RELEASE; TISSUE REACTION; WEIGHT CHANGE; ANALOGS AND DERIVATIVES; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; DRUG RELEASE; TANDEM MASS SPECTROMETRY; THEORETICAL MODEL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; MICROSPHERES; MODELS, THEORETICAL; PARTICLE SIZE; RISPERIDONE; SUCROSE; TANDEM MASS SPECTROMETRY;

EID: 84943585084     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1731-1     Document Type: Article

References (42)

1. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181-98.
2. Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry. 2014;29 Suppl 2(14):1409-13.
3. Hoybye C, Christiansen JS. Growth hormone replacement in adults - current standards and new perspectives. Best Pract Res Clin Endocrinol Metab. 2015;29(1):115-23.
4. Jiang Y, Wang F, Xu H, Liu H, Meng Q, Liu W. Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation. Int J Pharm. 2014;475(1-2):475-84.
5. Doan TV, Couet W, Olivier JC. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm. 2011;414(1-2):112-7.
6. Hu Z, Liu Y, Yuan W, Wu F, Su J, Jin T. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloids Surf B: Biointerfaces. 2011;86(1):206-11.
7. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24.
8. Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS. Injectable controlled release depots for large molecules. J Control Release. 2014;190:240-53.
9. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008;364(2):298-327.
10. Wang J, Wang BA, Schwendeman SP. Characterization of the initial burst release of a model peptide from poly(D, L-lactide-co-glycolide) microspheres. J Control Release. 2002;82(2-3):289-307.
11. Yang J, Wilson M, Celniker A. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect. J Control Release. 1997;49(97):193-205(13).
12. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R&D. 2005;6(3):129-37.
13. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91-100.
14. Sun F, Sui C, Teng L, Liu X, Teng L, Meng Q, et al. Studies on the preparation, characterization and pharmacological evaluation of tolterodine PLGA microspheres. Int J Pharm. 2010;397(1-2):44-9.
15. Luan X, Bodmeier R. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly(lactide-co-glycolide) microparticles. Eur J Pharm Biopharm. 2006;63(2):205-14.
16. Su Z, Sun F, Shi Y, Jiang C, Meng Q, Teng L, et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D, L-lactide-co-glycolide) microsphere. Chem Pharm Bull (Tokyo). 2009;57(11):1251-6.
17. Husmann M, Schenderlein S, Luck M, Lindner H, Kleinebudde P. Polymer erosion in PLGA microparticles produced by phase separation method. Int J Pharm. 2002;242(1-2):277-80.
18. Berkland C, King M, Cox A, Kim K, Pack DW. Precise control of PLG microsphere size provides enhanced control of drug release rate. J Control Release. 2002;82(1):137-47.
19. Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 2003;20(7):1055-62.
20. Gao Z, Ding P, Zhang L, Shi J, Yuan S, Wei J, et al. Study of a pingyangmycin delivery system: Zein/Zein-SAIB in situ gels. Int J Pharm. 2007;328(1):57-64.
21. Kraeling RR, Barb CR, Rampacek GB, Thompson Jr DL, Gibson JW, Sullivan SA, et al. Luteinizing hormone response to controlled-release deslorelin in estradiol benzoate primed ovariectomized gilts. Theriogenology. 2000;53(9):1681-9.
22. Shi X, Lin X, Yao C, Shen L, Feng Y. Injectable long-acting in situ forming systems for Radix Ophiopogonis polysaccharide. Int J Biol Macromol. 2015;72:553-9.
23. Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, Sane S, et al. Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials. 2002;23(22):4353-8.
24. Pechenov S, Shenoy B, Yang MX, Basu SK, Margolin AL. Injectable controlled release formulations incorporating protein crystals. J Control Release: Off J Control Release Soc. 2004;96(1):149-58.
25. Lin X, Yang S, Gou J, Zhao M, Zhang Y, Qi N, et al. A novel risperidone-loaded SAIB-PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo. J Mater Sci Mater Med. 2012;23(2):443-55.
26. Lu Y, Tang X, Cui Y, Zhang Y, Qin F, Lu X. In vivo evaluation of risperidone-SAIB in situ system as a sustained release delivery system in rats. Eur J Pharm Biopharm. 2008;68(2):422-9.
27. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2-3):121-36.
28. Lu YX, Yu YL, Tang X. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci. 2007;96(12):3252-62.
29. Hogan M. DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine). 2014 February 12. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=1899590.
30. Qi F, Wu J, Yang T, Ma G, Su Z. Mechanistic studies for monodisperse exenatide-loaded PLGA microspheres prepared by different methods based on SPG membrane emulsification. Acta Biomater. 2014;10(10):4247-56.
31. Qi F, Wu J, Fan QZ, He F, Tian GF, Yang TY, et al. Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability. Colloids Surf B: Biointerfaces. 2013;112(3):492-8.
32. Piacentini E, Drioli E, Giorno L. Membrane emulsification technology: twenty-five years of inventions and research through patent survey. J Membr Sci. 2014;468(20):410-22.
33. Thomas C, Gupta V, Ahsan F. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res. 2010;27(5):905-19.
34. Tran VT, Benoit JP, Venier-Julienne MC. Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int J Pharm. 2011;407(1-2):1-11.
35. Procter BG, Chappel CI. Subchronic toxicity studies of sucrose acetate isobutyrate (SAIB) in the rat and dog. Food Chem Toxicol. 1998;36(2):101-10.
36. Reynolds RC. Metabolism and pharmacokinetics of sucrose acetate isobutyrate (SAIB) and sucrose octaisobutyrate (SOIB) in rats, dogs, monkeys or humans: a review. Food Chem Toxicol. 1998;36(2):95-9.
37. Reynolds RC, Chappel CI. Sucrose acetate isobutyrate (SAIB): historical aspects of its use in beverages and a review of toxicity studies prior to 1988. Food Chem Toxicol. 1998;36(2):81-93.
38. Phillips JC, Kingsnorth J, Rowland I, Gangolli SD, Lloyd AG. Studies on the metabolism of sucrose acetate isobutyrate in the rat and in man. Food Cosmet Toxicol. 1976;14(5):375-80.
39. Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res. 1993;27(9):1135-48.
40. Huffman K, Casey D. Effect of carboxyl end groups on hydrolysis of polyglycolic acid. J Polym Sci Polym Chem Ed. 1985;23(7):1939-54.
41. Kazazi-Hyseni F, Zandstra J, Popa ER, Goldschmeding R, Lathuile AA, Veldhuis GJ, et al. Biocompatibility of poly(d, l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection. Int J Pharm. 2015;482(1-2):99-109.
42. Pajander J, Soikkeli AM, Korhonen O, Forbes RT, Ketolainen J. Drug release phenomena within a hydrophobic starch acetate matrix: FTIR mapping of tablets after in vitro dissolution testing. J Pharm Sci. 2008;97(8):3367-78.